# Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

> **NCT03472326** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 21 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** GS-9131
- **DRUG:** BIC
- **DRUG:** TAF
- **DRUG:** ARV regimen
- **DRUG:** DRV
- **DRUG:** RTV

## Key facts

- **NCT ID:** NCT03472326
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-03
- **Primary completion:** 2019-12-09
- **Final completion:** 2019-12-09
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** GS-9131 did not meet the targeted antiviral response
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472326, "Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03472326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*